Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13224)	12/17/2003 2:13:28 PM
From: Montana Wildhack	Respond to of 14101

I get $300k US for Italian sales roughly. This compares to $383k US for Canada in it's 1st 3 months.

To: Cal Gary who wrote (13224)	12/18/2003 11:45:07 AM
From: winzer5	Respond to of 14101

Globe says Dimethaid lotion gives good motion 2003-12-18 09:02 ET - In the News The Globe and Mail reports in its Thursday, Dec. 18, edition that Dimethaid Research saw its stock surge seven Canadian cents to finish at $1.06 (Canadian) in Toronto Wednesday after the drug developer announced quarterly sales of its lead product will grow to $1.2-million (U.S.), more than 70 per cent higher than the previous quarter. Volume was a heavy 3.1 million shares. The company also said total revenue for the second quarter, ended Nov. 30, will exceed $1.4-million (U.S.) and that sales of Pennsaid -- an osteoarthritis lotion -- will continue growing throughout the remainder of the fiscal year. Dimethaid expects to report its second quarter results in mid-January. The company is negotiating for sale of Pennsaid with marketing and sales organizations in Finland, Greece, Iceland and Portugal, it said. The day's gains reversed part of the stock's 19-Canadian-cent decline on Tuesday. Winzer